The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The role of cardiac glycosides in treating patients with chronic heart failure and normal sinus rhythm remains controversial. We studied the effect of digoxin on mortality and hospitalization in a randomized, double-blind clinical trial. METHODS: In the main trial, patients with a left ventricular ejection fraction of 0.45 or less were randomly assigned to digoxin (3397 patients) or placebo (3403 patients) in addition to diuretics and angiotensin-converting-enzyme inhibitors (median dose of digoxin, 0.25 mg per day; average follow-up, 37 months). In an ancillary trial of patients with ejection fractions greater than 0.45, 492 patients were randomly assigned to digoxin and 496 to placebo. RESULTS: In the main trial, mortality was unaffected. There were 1181 deaths (34.8 percent) with digoxin and 1194 deaths (35.1 percent) with placebo (risk ratio when digoxin was compared with placebo, 0.99; 95 percent confidence interval, 0.91 to 1.07; P=0.80). In the digoxin group, there was a trend toward a decrease in the risk of death attributed to worsening heart failure (risk ratio, 0.88; 95 percent confidence interval, 0.77 to 1.01; P=0.06). There were 6 percent fewer hospitalizations overall in that group than in the placebo group, and fewer patients were hospitalized for worsening heart failure (26.8 percent vs. 34.7 percent; risk ratio, 0.72; 95 percent confidence interval, 0.66 to 0.79; P<0.001). In the ancillary trial, the findings regarding the primary combined outcome of death or hospitalization due to worsening heart failure were consistent with the results of the main trial. CONCLUSIONS: Digoxin did not reduce overall mortality, but it reduced the rate of hospitalization both overall and for worsening heart failure. These findings define more precisely the role of digoxin in the management of chronic heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Suspected digoxin toxicity was higher in the digoxin group.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [74]
In the citing paper
“There were fewer patients hospitalized for worsening HF in the digoxin group.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [74]
In the citing paper
“There was no difference in all-cause mortality between groups.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [74]
In the citing paper
“In the randomized Digitalis Investigation Group (DIG) trial, digoxin had no effect on mortality compared to placebo in HFrEF patients in sinus rhythm (RR 0.99; 95% CI 0.91-1.07),but reduced hospital admissions (RR 0.72; 95% CI 0.66-0.79). 544,545”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [544]
In the citing paper
“In the randomized Digitalis Investigation Group (DIG) trial, digoxin had no effect on mortality compared to placebo in HFrEF patients in sinus rhythm (RR 0.99; 95% CI 0.91-1.07),but reduced hospital admissions (RR 0.72; 95% CI 0.66-0.79). 544,545”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [544]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
Packer, M., Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G. H., Bommer, W. J., Elkayam, U., Kukin, M. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252103 · Cited by 2,225
Packer, M., Gheorghiade, M., Young, J. B., Costantini, P. J., Adams, K. F., Cody, R. J., Smith, L. K., Van Voorhees, L., Gourley, L. A., & Jolly, M. K. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307013290101 · Cited by 827
Uretsky, B. F., Young, J. B., Shahidi, F. E., Yellen, L. G., Harrison, M. C., & Jolly, M. K. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90403-n · Cited by 582
A nomogram for digoxin therapy
Jelliffe, R. W., & Brooker, G. (1974) · The American Journal of Medicine · doi:10.1016/0002-9343(74)90769-4 · Cited by 149
The Digitalis Investigation Group (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00065-8 · Cited by 133
Self-citationJaeschke, R., Guyatt, G. H., & Oxman, A. D. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90154-6 · Cited by 117
Digitalis--a new controversy regarding an old drug. The pitfalls of inappropriate methods.
Yusuf, S., Wittes, J. T., Bailey, K. R., & Furberg, C. D. (1986) · Circulation · doi:10.1161/01.cir.73.1.14 · Cited by 86
Yusuf, S., Garg, R., Held, P. H., & Gorlin, R. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91255-3 · Cited by 71
Digoxin in heart failure: Implications of recent trials
Kelly, R. A., & Smith, T. W. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90472-d · Cited by 48
Yusuf, S. (1990) · Springer eBooks · doi:10.1007/978-3-642-75326-8_18 · Cited by 5
Research works printed but not linked: 1
- Yusuf S, 1990, Circulation, 82, III
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Metadata
- Authors
- The Digitalis Investigation Group
- Affiliations
- Mount Sinai Hospital (US)
- Corresponding author
- The Digitalis Investigation Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-02-20
- Volume
- 336
- Issue
- 8
- Pages
- 525-533
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945068164
- Cited by
- 3,016
- References
- 10
- Citations by year
- 2026: 74 · 2025: 66 · 2024: 70 · 2023: 82 · 2022: 90 · 2021: 91 · 2020: 88 · 2019: 73 · 2018: 92 · 2017: 102 · 2016: 124 · 2015: 103 · 2014: 96 · 2013: 95 · 2012: 89
- FWCI
- 96.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- digoxin, chronic heart failure, mortality, hospitalization, worsening heart failure, cardiac glycosides, left ventricular ejection fraction, ACE inhibitors, diuretics
- MeSH terms
- Aged, Arrhythmias, Cardiac, Cardiotonic Agents, Cardiovascular Diseases, Digoxin, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. https://app.cochat.ai/papers/10.1056/nejm199702203360801
- The paper
- The Digitalis Investigation Group. (1997). The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. New England Journal of Medicine. https://doi.org/10.1056/nejm199702203360801
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.